BioData Mining

In this work, we present a machine learning model for identifying pathogenic DNA variants. The model was learned from the analysis of normal and pathogenic sequences extracted from the ClinVar database (supported by NCBI). This analysis was based on a conceptual semantic model of DNA sequences converted to peptide sequences (amino acid sequences) governed by a well-defined grammar, which allowed us to apply NLP techniques, specifically Part of Speech tagging (POS tagging). Our predictive model was built by combining two techniques: CRF (from the Markov model family), which performs the sequencing, and BiLSTM (a deep learning model) which captures the past and future content of the sequences. The training space was created with the sequences of 105 genes associated with approximately 27,000 pathogenic variants. The model was evaluated using the metrics precision, P-R and ROC curves, AUC, and confusion matrices. Its performance was also compared against five known methods for predicting pathogenic variants. The results show exceptional performance that exceeds expectations and places this new method at the state of the art for predicting pathogenic DNA sequences.

Manual extraction of high-fidelity gene-disease-phenotype information from human genetics literature is a labor-intensive task that requires trained human genetics researchers to read through many primary research papers. This presents a major challenge for maintaining up-to-date human disease genetic databases. Recent exploration into large language models (LLMs) opens new directions in automating this manual process. However, most approaches depend on pre-training, finetuning, or specialized generative artificial intelligence (GenAI) tools, but there is a lack of empirical evidence to show whether commercially-available LLMs can be directly used to reliably extract gene-disease-phenotype for human genetic diseases. Herein, we perform a benchmark of the use of three zero-shot prompted LLMs, namely GPT-4, DeepSeek and Claude, without task-specific fine-tuning, to extract human genetic information directly from full text of scientific papers. Using known congenital heart diseases (CHD) genes found in the open access CHDgene database (https://chdgene.victorchang.edu.au/) as the benchmark data set, GPT-4o achieved overall 88.8% extraction accuracy across 23 gene entries containing over 57 references, with 100% accuracy in gene name, 78.3% and 76.7% in disease and phenotype fields respectively. This work introduces a lightweight, easy-to-deploy, and yet robust LLM-based agent named GeneAgent, analyze sources of disagreement, and highlight the feasibility of integrating powerful LLM into genetic evidence synthesis workflows. Highlight- First systematic benchmark of LLMs for extracting human gene-disease-phenotype relationships from full-text biomedical articles - GeneAgent: a lightweight, highly accurate prompt-only LLM agent - New domain task-specific evaluation framework

Logistic regression remains a widely used classification method due to its interpretability and computational efficiency, but its direct application to high-dimensional biomedical data is limited when the number of features greatly exceeds the number of samples. In this paper, we propose a reformulated logistic regression framework designed for feature selection and classification in complex high-dimensional settings. The method is evaluated on three biomedical datasets, including scenarios with tens of thousands of attributes and substantially fewer samples. Across these datasets, the proposed approach achieved clear separation between control and disease groups while selecting a compact set of features. Several selected features were consistent with previously reported disease-associated markers, supporting the biological plausibility of the model, while additional selected features suggest potential novel candidates for further investigation. These results indicate that the proposed framework may provide an interpretable and computationally efficient alternative for feature selection in high-dimensional computational biology applications.

Adverse event report (AER) data are a key source of signal for post marketing drug surveillance. The standard methodology to analyze AER data applies disproportionality metrics, which estimate the strength of drug/side-effect associations from discrete counts of their occurrence at report level. However, in other domains, improvements in predictive modeling accuracy have been obtained through representation learning, where discrete features are replaced by distributed representations learned from unlabeled data. This paper describes aer2vec, a novel representational approach for AER data in which concept embeddings emerge from neural networks trained to predict drug/side-effect co-occurrence. Trained models are evaluated for their utility in identifying drug/side-effect relationships, with improvements over disproportionality metrics in most cases. In addition, we evaluate the utility of an otherwise-untapped resource in the Food and Drug Administration (FDA) AER system - reporter designations of suspected causality - and find that incorporating this information enhances performance of all models evaluated.

BackgroundAdverse drug-drug interactions (DDIs) cause preventable hospitalizations, but exhaustive experimental screening of all drug pairs is infeasible. Many computational predictors rely on SMILES or other molecular representations, limiting their direct applicability to biologics and other non-small-molecule therapeutics. We present a structure-agnostic framework that combines semantic representations derived from Medical Subject Headings (MeSH) with graph-derived topology from a Drug-Target-Protein knowledge graph constructed from DrugBank and UniProt. We further investigate how variation in MeSH annotation depth affects predictive performance. ResultsDrugs are grouped according to their deepest MeSH annotation level (Low, Mid, or Deep), and performance is evaluated across the resulting interaction categories in transductive and inductive settings. The Intermediate ontology scope (Low+Mid) provides the most stable performance, while adding Deep-level terms offers limited and inconsistent benefit. Lightweight topological descriptors are integrated with MeSH features through instance-wise, dimension-specific latent-space gating, using curated reliable-negative pairs for supervision. Fusion improves mean performance over the MeSH-only baseline across all six categories in the transductive setting. Under induction, the clearest gains occur for Low-Low interactions ({Delta}AUROC = 0.056;{Delta} F1 = 0.137) and Low-Mid interactions ({Delta}AUROC = 0.077;{Delta} F1 = 0.114). ConclusionsMeSH annotation depth is associated with systematic variation in DDI prediction performance that aggregate evaluation can obscure. Graph-derived topology is particularly beneficial when ontology annotations are shallow. The framework provides a common, structure-agnostic representation compatible with both small-molecule and biologic therapeutics and supports first-pass DDI prioritization for subsequent expert assessment.

Background: Extrauterine growth restriction (EUGR) is a common and clinically significant complication among preterm infants, contributing to adverse neurodevelopmental and metabolic outcomes. Early and individualized risk prediction remains challenging. This study aimed to develop and validate an interpretable machine learning model for early prediction of EUGR using routinely available clinical variables, and to implement a user-friendly web-based calculator for clinical use. Methods: We retrospectively analyzed 1,431 preterm infants admitted within 24 hours after birth to our hospital between May 2020 and March 2025. Infants from the Yangpu campus (n=863) formed the training set, and those from the Huangpu campus (n=568) formed the validation set. Early clinical variables available within 48-72 hours were screened using the Boruta algorithm. Logistic regression, XGBoost, random forest, decision tree, and support vector machine models were developed and compared. Model performance was evaluated using area under the curve (AUC), accuracy, sensitivity, specificity, F1 score, and Brier score. SHapley Additive exPlanations (SHAP) were applied to assess global and individual feature contributions, nonlinear effects, and interactions. A web-based calculator was constructed based on the optimal model. Results: Nine variables were identified as important predictors: birth weight, small for gestational age status, gestational age, breastfeeding, multiple gestation, neonatal respiratory distress syndrome, patent ductus arteriosus, maternal hypertension, and maternal group B Streptococcus infection. Among the five models, XGBoost achieved the best performance in the validation set (AUC 0.922, accuracy 0.849, Brier score 0.108). SHAP analysis showed that low birth weight, small for gestational age, maternal group B Streptococcus infection, and patent ductus arteriosus were major risk factors, while breastfeeding was protective. Notable nonlinear and interactive effects were observed, particularly between birth weight and gestational age and between breastfeeding and patent ductus arteriosus. The web-based calculator provides real-time individualized risk estimation and visualized interpretation. Conclusions: An interpretable XGBoost-based model and web calculator were successfully developed and validated for early prediction of EUGR in preterm infants. This tool may support clinicians in identifying high-risk infants and guiding individualized nutritional and clinical management.

Drug repurposing presents a potential solution for finding new therapies for rare and orphan diseases. The limited number of patients affected by rare diseases, combined with scarce research and the financial burden of clinical trials, creates a significant barrier to developing new drugs. Drug repurposing utilizes the known safety profile and effectiveness of existing medications to fast-track the development of life-saving therapies. Recently drug repurposing has focused on utilizing biomedical knowledge graphs to uncover hidden connections between diseases and drugs, revealing promising candidates for repurposing. Because most knowledge graphs in biomedical domain are made by text-mining scientific literature we decided to compare the amount of knowledge contained in open access and controlled (subscription only) access literature. Elsevier and Every Cure make logical partners and allowed the project to use Elseviers ability to access both controlled and open access publications and its proprietary Elsevier AI technology to construct the knowledge graph. Notwithstanding the fact that more than 50% of relationships in drug repurposing for rare diseases can be found in open access content, 45% of relationships remain only in controlled access. We argue that this is due to the large number of edges supported by single reference in the entire biomedical knowledge graph and does not reflect an intrinsic difference between open and controlled access.

ObjectiveTo develop and evaluate a personalized literature review system that efficiently processes and summarizes biomedical literature to provide timely, relevant insights for researchers. MethodsThe system integrates ontology-aware keyword extraction (MeSH/ACM constrained TF-IDF from CV/Research Statement), citation-informed retrieval (PubMed and NIH iCite API), and dual-model large language model (LLM) summarization (Google Gemini 2.0 flash, OpenAI GPT-4o-mini). These LLMs leverage advanced Transformer architectures, building on foundations such as BERT, BART, and BioBERT. A two-stage ranking algorithm combines Relative Citation Ratio (RCR) with cosine similarity. Summary quality was evaluated using ROGUE-1/2/L and BERTScore. The system is deployed as a Streamlit web application. ResultsAcross 20 biomedical queries, the system demonstrated strong average performance (BERT-F1{approx} 0.86), with cosine similarity strongly correlating with summary quality. Human evaluation involving 10 users yielded average scores above 4.5/5 across summary fidelity and keyword relevance. ConclusionHybrid ranking and ensemble LLM summarization significantly accelerate scientific sense-making. These findings suggest broad applicability to various domains beyond biomedicine.

Incorporating realistic sets of patient-associated covariates, i.e., virtual populations, in pharmacometric simulation workflows is essential to obtain realistic model predictions. Current covariate simulation strategies often omit or simplify dependency structures between covariates. Copula models are multivariate distribution functions suitable to capture dependency structures between covariates with improved performance compared to standard approaches. We aimed to develop and evaluate a copula model for generation of adult virtual populations for 12 patient-associated covariates commonly used in pharmacometric simulations, using the publicly available NHANES database, including sex, race-ethnicity, body weight, albumin, and several biochemical variables related to organ function. A multivariate (vine) copula was constructed from bivariate relationships in a stepwise fashion. Covariate distributions were well captured for the overall and subgroup populations. Based on the developed copula model, a web application was developed. The developed copula model and associated web application can be used to generate realistic adult virtual populations, ultimately to support model-based clinical trial design or dose optimization strategies.

BackgroundThis study addresses limitations of traditional medication adherence assessment tools by developing a machine learning model to evaluate post-discharge medication compliance in patients using drugs. The research was conducted at Nanjing Drum Tower Hospital from February 2024 to December 2024. MethodsWe collected clinical data from 240 patients through questionnaires and developed a multi-class machine learning model. Feature selection employed manual screening and polynomial logistic regression. Six ML models were evaluated, with the Random Forest Classifier (RFC) demonstrating optimal performance (bad_AUC = 0.979, fine_AUC = 0.973, good_AUC = 0.917). SHAP analysis was used to explain the best-performing model. ResultsThe RFC model showed superior predictive capability across all adherence levels. Model interpretation revealed key clinical factors influencing adherence patterns. The tool enables early identification of non-compliance and supports intervention strategies. ConclusionsThis RFC-based model represents a significant advancement in medication adherence assessment, offering clinicians a practical tool for monitoring compliance. The approach shows particular promise for enhancing mental health management in this patient population by fostering better medication awareness and establishing scientific medication habits during early treatment stages.

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy defined by aberrant clonal expansion of abnormal myeloid progenitor cells. Characterized by morphological, molecular, and genetic alterations, AML encompasses multiple distinct subtypes that would exhibit subtype-specific responses to treatment and prognosis, underscoring the critical need of accurately identifying AML subtypes for effective clinical management and tailored therapeutic approaches. Traditional wet lab approaches such as immunophenotyping, cytogenetic analysis, morphological analysis, or molecular profiling to identify AML subtypes are labor-intensive, costly, and time-consuming. To address these challenges, we propose AttentionAML, a novel attention-based deep learning framework for accurately categorizing AML subtypes based on transcriptomic profiling only. Benchmarking tests based on 1,661 AML patients suggested that AttentionAML outperformed state-of-the-art methods across all evaluated metrics (accuracy: 0.96, precision: 0.96, recall of 0.96, F1-score: 0.96, and Matthews correlation coefficient: 0.96). Furthermore, we also demonstrated the superiority of AttentionAML over conventional approaches in terms of AML patient clustering visualization and subtype-specific gene marker characterization. We believe AttentionAML will bring remarkable positive impacts on downstream AML risk stratification and personalized treatment design. To enhance its impact, a user-friendly Python package implementing AttentionAML is publicly available at https://github.com/wan-mlab/AttentionAML.

Diet plays a critical role in human health, with growing evidence linking dietary habits to disease outcomes. However, extracting structured dietary knowledge from biomedical literature remains challenging due to the lack of dedicated relation extraction datasets. To address this gap, we introduce RECoDe, a novel relation extraction (RE) dataset designed specifically for diet, disease, and related biomedical entities. RECoDe captures a diverse set of relation types, including a broad spectrum of positive association patterns and explicit negative examples, with over 5,000 human-annotated instances validated by up to five independent annotators. Furthermore, we benchmark various natural language processing (NLP) RE models, including BERT-based architectures and enhanced prompting techniques with locally deployed large language models (LLMs) to improve classification performance on underrepresented relation types. The best performing model gpt-oss-20B, a local LLM, achieved an F1-score of 64% for multi-class classification and 92% for binary classification using a hierarchical prompting strategy with a separate reflection step built in. To demonstrate the practical utility of RECoDe, we introduce the Contextual Co-occurrence Summarisation (Co-CoS) framework, which aggregates sentence-level relation extractions into document-level summaries and further integrates evidence across multiple documents. Co-CoS produces effect estimates consistent with established dietary knowledge, demonstrating its validity as a general framework for systematic evidence synthesis. AvailabilityThe code, models, and data will be made freely available upon acceptance.

Interpretation of a given variants pathogenicity is one of the most profound challenges to realizing the promise of genomic medicine. A large amount of information about associations between variants and diseases used by curators and researchers for interpreting variant pathogenicity is buried in biomedical literature. The development of text-mining tools that can extract relevant information from the literature will speed up and assist the variant interpretation curation process. In this work, we present a text-mining tool, MACE2k that extracts evidence sentences containing associations between variants and diseases from full-length PMC Open Access articles. We use different machine learning models (classical and deep learning) to identify evidence sentences with variant-disease associations. Evaluation shows promising results with the best F1-score of 82.9% and AUC-ROC of 73.9%. Classical ML models had a better recall (96.6% for Random Forest) compared to deep learning models. The deep learning model, Convolutional Neural Network had the best precision (75.6%), which is essential for any curation task.

Acute myocardial infarction (AMI) is one of the leading cardiovascular diseases worldwide and remains a major cause of mortality. Early risk prediction can help clinicians identify high risk patients shortly after admission and support timely monitoring and individualized treatment. Previous AMI risk assessment approaches predominantly rely on a single model structure or fixed feature representation, which may limit their ability to capture diverse risk related patterns and reduce predictive performance. To address these challenges, we propose MetaAMI, a random projection based meta-learning framework for AMI outcome prediction. Specifically, patients were selected based on ICD-9 and ICD-10 diagnostic codes for AMI from the Medical Information Mart for Intensive Care IV (MIMIC-IV) v3.1 database. Features were transformed through multiple random projections, with each random projection generating a distinct lower dimensional feature representation. Subsequently, baseline classifiers were trained on each lower dimension representation to predict in-hospital mortality among AMI patients. The predictions were aggregated to construct an integrated feature representation, which was used as input to a meta-learner architecture. By effectively integrating complementary information from diverse baseline models, the meta-learner refined the decision boundary and enhanced overall predictive performance. Survival analysis and SHapley Additive exPlanations (SHAP) analysis were further performed to evaluate clinical utility and interpret the model predictions. Benchmarking results based on MIMIC-IV dataset suggested that our MetaAMI consistently outperformed all the baseline classifiers across seven evaluation metrics including Accuracy, Area Under the Curve (AUC), F1 Score, G-Measure, Jaccard Index, Youden J, and Matthews Correlation Coefficient (MCC). In addition, feature importance analysis showed clinically relevant predictors of in-hospital mortality. In summary, MetaAMI provides an effective and robust solution for machine learning based AMI risk prediction. We anticipate that the application of MetaAMI will have a positive impact on clinical risk stratification and personalized treatment strategies for AMI.

Traditional pharmacovigilance systems rely on adverse event reports received by regulatory authorities such as the United States Food and Drug Administration (FDA). These traditional systems suffer from underreporting and are not timely due to their reliance on third-party sentinels. To address these issues, the MedWatcher Social system for monitoring adverse events through automated processing of digital social media data and crowdsourcing was launched in 2012 by Boston Childrens Hospital and the FDA. The system is rooted in the well-established FDA MedWatch system.\n\nMedWatcher Social uses an indicator score approach to identify adverse events. This study evaluates the MedWatcher Social adverse event classifiers performance on Twitter data and proposes an enhancement to the indicator score method that results in improved adverse event identification.\n\nOur research suggests that automatic pharmacovigilance systems using the original indicator score approach should be updated. Careful consideration of modeling assumptions is critical when designing algorithms for computational epidemiology, and algorithms should be regularly reevaluated to identify enhancements and to remedy concept drift.

In recent years, the development of natural language process (NLP) technologies and deep learning hardware has led to significant improvement in large language models(LLMs). The ChatGPT, the state-of-the-art LLM built on GPT-3.5, shows excellent capabilities in general language understanding and reasoning. Researchers also tested the GPTs on a variety of NLP related tasks and benchmarks and got excellent results. To evaluate the performance of ChatGPT on biomedical related tasks, this paper presents a comprehensive benchmark study on the use of ChatGPT for biomedical corpus, including article abstracts, clinical trials description, biomedical questions and so on. Through a series of experiments, we demonstrated the effectiveness and versatility of Chat-GPT in biomedical text understanding, reasoning and generation.

Recent advancements in Large Language Models (LLMs) have ushered in a new era for knowledge extraction in the domains of biological and clinical natural language processing (NLP). In this research, we present a novel approach to understanding the regulatory effects of genes and medications on biological processes central to wound healing. Utilizing the capabilities of Generative Pre-trained Transformer (GPT) models by OpenAI, specifically GPT-3.5 and GPT-4, we developed a comprehensive pipeline for the identification and grounding of biological processes and the extraction of such regulatory relations. The performances of both GPTs were rigorously evaluated against a manually annotated corpus of 104 PubMed titles, focusing on their ability to accurately identify and ground biological process concepts and extract relevant regulatory relationships from the text. Our findings demonstrate that GPT-4, in particular, exhibits superior performance in all the tasks, showcasing its potential to facilitate significant advancements in biomedical research without requiring model fine-tuning.

Since the release of ChatGPT in 2022, AI-generated texts have inevitably permeated various types of writing, sparking debates about the quality and quantity of content produced by such large language models (LLM). This study investigates a critical question: Have AI-generated texts from LLM infiltrated the realm of scientific writing, and if so, to what extent and in what setting? By analyzing a dataset comprised of preprint manuscripts uploaded to arXiv, bioRxiv, and medRxiv over the past two years, we confirmed and quantified the widespread influence of AI-generated texts in scientific publications using the latest LLM-text detection technique, the Binoculars LLM-detector. Further analyses with this tool reveal that: (1) the AI influence correlates with the trend of ChatGPT web searches; (2) it is widespread across many scientific domains but exhibits distinct impacts within them (highest: computer science, engineering sciences); (3) the influence varies with authors who have different language speaking backgrounds and geographic regions according to the location of their affiliations (Italy, China, etc.); (4) AI-generated texts are used in various content types in manuscripts (most significant: hypothesis formulation, conclusion summarization); (5) AI usage has a positive influence on papers impact, measured by its citation numbers. Based on these findings, suggestions about the advantages and regulation of AI-augmented scientific writing are discussed.

Background Large Language Models (LLMs) are increasingly explored for pharmacovigilance tasks, including information extraction, case documentation, and single-case causality assessment. However, their ability to support causality assessment at the case series level -- a complex, time-intensive task requiring clinical reasoning across multiple reports -- remains unexplored. Objective To investigate how a large-scale general-purpose LLM can support pharmacovigilance professionals in assessing causality in a case series, and to explore how prompt design influences the quality of the model's reasoning. Methods GPT-4o was used to assess causality for five drug - adverse event combinations, using an adaptation of the Bradford Hill viewpoints for case series assessment. The combinations represented varying drugs and vaccines, adverse events, and case series sizes (5-402 reports). One combination served as a negative control. Structured prompts were iteratively developed and refined using one combination, then applied to all combinations. LLM-generated assessments for each viewpoint were qualitatively evaluated by human annotators for accuracy (precision), and the LLM's coverage of key aspects from the original signal text was assessed for one combination (recall). Results Across all five combinations, annotators agreed with 79-92% of the LLM's output sentences. Full disagreement was consistently low (3-7%), with errors typically involving misinterpretation of complex report details rather than outright fabrication. Prompt design substantially influenced output quality; providing Bradford Hill viewpoint descriptions, including case series data, and adding explicit anti-hallucination instructions improved specificity and grounding. For the recall assessment, 15 of 23 key segments from the original signal text were reflected in the LLM output. The overall summary assessments demonstrated balanced reasoning, correctly distinguishing between positive safety signals and the negative control, and provided a coherent synthesis suitable as a starting point for human assessors. Conclusions LLMs have the potential to generate contextually nuanced and largely accurate preliminary causality assessments of case series aligned with the Bradford Hill viewpoints, with a low but non-zero hallucination rate. These findings support LLMs as a tool to augment, not replace, expert judgment in signal assessment. Future work should address larger and more diverse signal sets, improved evaluation frameworks for generative output, and the integration of pre-computed summary statistics to reduce errors.

Medulloblastoma is a childhood brain tumor traditionally classified into four molecular subgroups. Recent evidence suggests that Groups 3 and 4 represent a biological continuum rather than distinct entities, a paradigm shift with significant implications for understanding disease biology and treatment strategies. Nevertheless, assessing this hypothesis is challenging mainly due to data scarcity. In this study, we analyze the largest available transcriptomics dataset to provide compelling evidence for the existence of an intermediate subgroup between Groups 3 and 4, characterized by distinct molecular features. To overcome limitations posed by data scarcity, we employ synthetic data generation using a Variational Autoencoder and apply explainability techniques to identify key relationships between gene expression and disease subgroups. Furthermore, by incorporating Machine Learning Fairness approaches, we demonstrate that overlooking this intermediate subgroup can result in treatment disparities. Our findings are further supported by both existing and newly proposed studies using diverse datasets and methodologies, including graphbased analyses and multi-scale simulations, underscoring the robustness and reproducibility of our results. This study demonstrates the potential of synthetic data generation to refine rare disease subtyping and advance our understanding of the underlying biological mechanisms. Keywords: Medulloblastoma, pediatric cancer, representation learning, autoencoder, synthetic data